Regulatory Bayer wins MHRA approval for Kerendia in heart failure PharmaTimesNew authorisation offers additional option for patients with lvef 40%RegulatoryCardiovascularRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) PharmaTimes New authorisation offers additional option for patients with lvef 40% RegulatoryCardiovascularRead full story Post navigation Previous: Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumorsNext: FDA hands another rejection to Replimune’s melanoma therapy Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026